Covington, Goodwin Guide Bristol Myers' $1.5B Orbital Buy

Bristol Myers Squibb plans to acquire privately held Orbital Therapeutics for $1.5 billion in cash, aiming to expand its pipeline in cell- and RNA-based therapies for autoimmune diseases, the companies announced...

Already a subscriber? Click here to view full article